{
    "clinical_study": {
        "@rank": "21629", 
        "arm_group": [
            {
                "arm_group_label": "LDCB", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel Coated Balloon"
            }, 
            {
                "arm_group_label": "PTA", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard Uncoated Balloon Angioplasty Catheter PTA Catheter"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate the safety and efficacy of  MD02-LDCB for treatment of stenosis or occlusion\n      of the femoral and popliteal arteries in the Japanese population."
        }, 
        "brief_title": "LEVANT Japan Clinical Trial", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Femoral Arterial Stenosis", 
            "Stenosis of Popliteal Arteries", 
            "Femoral Artery Occlusion", 
            "Occlusion of Popliteal Arteries"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Arterial Occlusive Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will enroll patients presenting with claudication or ischemic rest pain and an\n      angiographically significant lesion in the superficial femoral or popliteal artery and a\n      patent outflow artery to the foot.  After successful protocol-defined pre-dilatation,\n      subjects that are determined not to require stenting based on defined angiographic criteria\n      are randomized 2:1 to treatment with either MD02-LDCB (test arm) or standard PTA catheter\n      (control arm) using similar techniques. Subjects that do not meet post-predilatation lesion\n      criteria are excluded (and treated per standard practice) and followed for safety for 30\n      days. Randomized subjects will have ultrasound follow-up through 2 years and are consented\n      for up to 2 years clinical follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant female \u226520 years of age;\n\n          -  Rutherford Clinical Category 2-4;\n\n          -  Length \u226415 cm;\n\n          -  \u226570% stenosis\n\n          -  Lesion location starts \u22651 cm below the common femoral bifurcation and terminates\n             distally \u22642 cm below the tibial plateau AND  \u22651 cm above the origin of the TP trunk;\n\n          -  A patent inflow artery as confirmed by angiography\n\n          -  At least one patent native outflow artery to the ankle\n\n        Exclusion Criteria:\n\n          -  Life expectancy of < 2 years;\n\n          -  History of hemorrhagic stroke within 3 months;\n\n          -  Previous or planned surgical or interventional procedure within 2 weeks before or\n             within 30 days after the index procedure;\n\n          -  History of MI, thrombolysis or angina within 2 weeks of enrollment;\n\n          -  Renal failure or chronic kidney disease\n\n          -  Severe calcification that renders the lesion un-dilatable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816412", 
            "org_study_id": "MD02-LDCB"
        }, 
        "intervention": [
            {
                "arm_group_label": "LDCB", 
                "intervention_name": "MD02-LDCB Paclitaxel coated balloon catheter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PTA", 
                "intervention_name": "Standard Uncoated Balloon Angioplasty Catheter", 
                "intervention_type": "Procedure", 
                "other_name": "PTA Catheter"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Arms", 
            "Experimental", 
            "Drug Coated Angioplasty Balloon", 
            "Active Comparator", 
            "Standard angioplasty balloon"
        ], 
        "lastchanged_date": "March 25, 2013", 
        "location": {
            "contact": {
                "last_name": "Osamu Iida", 
                "phone": "06-6416-1221"
            }, 
            "facility": {
                "address": {
                    "city": "Amagasaki-shi", 
                    "country": "Japan", 
                    "state": "Hyogo-ken.", 
                    "zip": "3-1-69"
                }, 
                "name": "Kansai Rosai Hospital."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Single Blind, Randomized, Controlled Japanese Population Trial Comparing MD02-LDCB Versus Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries", 
        "overall_official": [
            {
                "affiliation": "Kokura Memorial Hospital Cardiovascular Internal Medicine", 
                "last_name": "Hiroyoshi Yokoi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kansai Rosai Hospital Cardiovascular Internal Medicine", 
                "last_name": "Osamu lida", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: MHLW LEVANT Japan study is conducted according to Declaration of Helsinki, Standards stipulated in Article 14, Paragraph 3 & Article 80-2 of the PAL, and Medical Device GCP Ministerial Ordinance\".", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary Patency", 
            "measure": "Composite of freedom from all-cause peri-operative (\u226430 day) death and freedom at 6 months from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816412"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Composite of freedom from all-cause peri-operative (\u226430 day) death and freedom at 6 months from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6, 12 and 24 months"
            }, 
            {
                "description": "Primary Patency of the target lesion at 6 months. Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) \u22652.5) and freedom from target lesion revascularization (TLR).", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6, 12 and 24 months"
            }
        ], 
        "source": "C. R. Bard", 
        "sponsors": {
            "collaborator": {
                "agency": "Medicon, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "C. R. Bard", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}